Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Accelerating sustainability in Indian pharma industry
Subscribe To Our Newsletter & Stay Updated
